Abstract library

680 results for "first line".
#1750 Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: doctor Belabdi Djihed
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1528 Medullary Thyroid Carcinoma Cell Lines – An Update
Introduction: Medullary Thyroid Carcinoma (MTC) originates from calcitonin-producing neuroendocrine C-cells of the thyroid gland. Mutations in the RET-proto-oncogene are associated with both sporadic and familial MTC. As MTC are poorly responsive to chemo- and radiation- therapy, surgery is the only curative treatment at the moment. The cytogenetics of MTC have been sparsely investigated because the cells are very difficult to cultivate. In the last three decades our research group has established 10 continues cell lines derived from primary tumor and lymph node metastasis of patients with either sporadic or hereditary MTC.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Gert Schwach
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors: Rho Y S, Gilabert M, McLean J, Kavan P, ...
#198 Novel Insights in Octreotide Effects on Human Neuroendocrine Cell Line CNDT2.5
Introduction: Octreotide, the first synthetic somatostatin analog available for clinical use, efficiently binds somatostatin receptors (SSRs) 2 and 5 and may transduce its effects by using SSRs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Cui T, Martijn C, Öberg K, ...
#2296 First Patient Survey about Tumor - Associated Fatigue in NEN
Introduction: Tumor-associated fatigue (TrF) is a debilitating condition occurring during the course of the tumor disease, and even ongoing after all tumor specific therapies are completed. The syndrome consists of chronic fatigue, sleep disturbances, severe pain, brain-fog and is underestimated by both, patients and doctors. Diagnosis is made according to the criteria by Cella (Cella 2001), although it is felt not to be sufficient.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PD Dr. Patricia Grabowski
#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
#1115 Cancer Stem Cells in Small Intestine Neuroendocrine Cell Line P-STS: Isolation and Molecular Characterisation
Introduction: Cancer stem cells (CSCs) represent a small subpopulation of tumour cells responsible for invasive tumour growth. Even though the presence of CSCs in neuroendocrine tumours is documented, their role in neuroendocrine tumourigenesis and metastasis is not defined as yet.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Florian Kleinegger
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors: Thirlwell C, Sasmaz S, Dibra H, Feber A, ...